Skip to main content

Table 4 Results of gene-based tests. Results from gene-based tests with MAGMA representing the joint effects of common SNPs within the named gene (NB: for PC1 no genome-wide significant gene-based results were observed)

From: Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

Outcome

Gene

Chr

Start

End

Nsnps

Z

P

Genome-wide significant genes

Aβ Pathology (PC2)

APOE

19

45409011

45412650

6

7.91

1.3E−15

Injury/Inflammation (PC3)

TMEM106B

7

12250867

12282993

182

5.75

4.6E−09

Non-AD Inflammation (PC4)

CHI3L1

1

203148059

203155877

28

4.53

2.9E−06

Non-AD Synaptic Functioning (PC5)

GRIN2D

19

48898132

48948188

110

4.63

1.8E−06

Comparison with rare-variant hits

 Injury/Inflammation

IFFO1

12

6647541

6665239

46

0.50

0.307

 Injury/Inflammation

DTNB

2

25600067

25896503

385

−1.11

0.867

 Injury/Inflammation

NLRC3

-

-

-

-

-

-

 Injury/Inflammation

SLC22A10

11

62905339

63137190

564

−1.79

0.963

 Non-AD Synaptic Functioning

GABBR2

9

101050391

101471479

1445

1.41

0.079

 Non-AD Synaptic Functioning

CASZ1

1

10696661

10856707

387

0.32

0.374

  1. Chr chromosome, Start/End SNPs between start and end were considered, Nsnps number of SNPs included in test, Z Z test statistic, p p-value